Additionally, during disease progression neutrophils secrete increasing amounts of interferon-γ (IFN-γ) in response to MM soluble factors, thereby increasing MM JAK-2/STAT3 pathway activation that supports myeloma survival (123). Here, JAK2 is linked to Miyoshi myopathy.